BOXIT (bladder cancer)
The BOXIT trial compared standard treatment and celecoxib (an anti-inflammatory drug) with standard treatment alone for bladder cancer. Celecoxib is a type of drug called a COX-2 inhibitor. COX-2 inhibitors block the action of a protein that may help cancer cells to grow.
We recruited patients with a very early type of bladder cancer called superficial transitional cell bladder cancer. This trial was supported by Cancer Research UK.
Superficial transitional cell bladder cancer is usually treated by removing the cancer (tumours) from the bladder. This procedure is called a transurethral resection of bladder tumours, or TURBT. Some people will also have treatment into the bladder (intravesical). For example, intravesical chemotherapy or intravesical BCG. Despite this treatment, some people have an increased risk of their bladder cancer coming back (recurring).
The trial aimed to find out if adding celecoxib to standard treatment would be better at stopping the cancer from growing back and so improve treatment.
472 patients were recruited from UK sites over a five year period. Patients received either 400 mg celecoxib daily for 2 years or a placebo, in addition to standard therapy. Patients are being followed up for up to 10 years.
The BOXIT trial is now completed we expect to publish the results as soon as possible.